Clinical Features, Diagnosis, and Management of the Antiphospholipid Syndrome

Richard C. W. Wong; Emmanuel J. Favaloro

doi:10.1055/s-0028-1082275

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2008; 34(3): 295-304
DOI: 10.1055/s-0028-1082275

Clinical Features, Diagnosis, and Management of the Antiphospholipid Syndrome

Richard C.W Wong¹ , Emmanuel J. Favaloro²

¹Division of Immunology, Pathology Queensland, Royal Brisbane and Womens Hospital, Herston, Queensland, Australia
²Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, NSW, Australia

Abstract

ABSTRACT

Almost 30 years after it was first described as a discrete clinical entity, the antiphospholipid syndrome (APS) remains a challenge for clinicians in a wide range of specialities. There remain ongoing issues regarding nomenclature, the expanding range of clinical manifestations, and management of certain APS patient subgroups. In addition to the presence of appropriate clinical features, the diagnosis of APS also fundamentally requires the finding of positive antiphospholipid antibody test result(s), and unfortunately much still has to be done to improve the robustness, reproducibility, and standardization of these assays. This article discusses ongoing dilemmas and issues related to clinical aspects of APS including (i) the derivation of the current nomenclature and the implications of recent proposals for its revision; (ii) the problems that the protean clinical manifestations pose for many clinicians, in particular those not intimately familiar with APS; (iii) the potential pitfalls of applying the APS classification criteria as diagnostic criteria (although no doubt tempting for nonspecialist clinicians); (iv) the concept of seronegative APS and the effect that recent proposed changes in antiphospholipid antibody testing strategies may have on this diagnosis; and finally (v) an overview of key developments in the clinical management of APS patients over the past 30 years.

KEYWORDS

Anti-β2GPI antibodies - anticardiolipin antibodies - antiphospholipid antibodies - aPL - antiphospholipid syndrome - APS - clinical features - criteria - diagnosis - management

Full Text

References

REFERENCES

1 Miyakis S, Lockshin M D, Atsumi T et al.. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4 295-306
2 Wong R C, Favaloro E J. Antiphospholipid antibodies and the antiphospholipid syndrome I: pathogenesis, clinical features, diagnosis, and management. Semin Thromb Hemost. 2008; 34 213-218
3 Favaloro E J, Wong R C. Antiphospholipid antibodies and the antiphospholipid syndrome II: limitations, standardisation, and clinical utility of laboratory testing. Semin Thromb Hemost. 2008; 34 , (in press)
4 Hughes G. Hughes syndrome. The antiphospholipid syndrome—a clinical overview. Clin Rev Allergy Immunol. 2007; 32 3-11
5 Harris E N, Pierangeli S S. Primary, secondary, and catastrophic antiphospholipid syndrome: what's in a name?. Semin Thromb Hemost. 2008; 34 219-226
6 Asherson R A. The primary, secondary, catastrophic, and seronegative variants of the antiphospholipid syndrome: a personal history long in the making. Semin Thromb Hemost. 2008; 34 227-235
7 Roubey R. Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum. 1996; 39 1444-1454
8 Seisdedos L, Muñoz-Rodriguez F J, Cervera R, Font J, Ingelmo M. Primary antiphospholipid syndrome evolving into systemic lupus erythematosus. Lupus. 1997; 6 285-286
9 Gómez-Puerta J A, Martin H, Amigo M-C et al.. Long term follow-up in 128 patients with primary antiphospholid syndrome. Do they develop lupus?. Medicine. 2005; 84 225-230
10 Meroni P L, Tincani A. 12th International Congress on Anti-Phospholipid Antibodies. 2007. Available at: http://www.antiphospholipid.net/committees.html Accessed April 7, 2008
11 Asherson R A, Schamroth-Rapaport N, Skudowitz B et al.. Recurrent deep vein thrombosis, ovarian carcinoma and antibodies to mitochondria M5 in a patient with asymptomatic primary “plus” antiphospholipid syndrome: an unusual combination. Clin Exp Rheumatol. 2007; 25 890-895
12 Asherson R A, Cervera R, Merrill J T, Erkan D. Antiphospholipid antibodies and the antiphospholipid syndrome: clinical significance and treatment. Semin Thromb Hemost. 2008; 34 256-266
13 Blume J E, Miller C C. Antiphospholipid syndrome: a review and update for the dermatologist. Cutis. 2006; 78 409-415
14 Miesbach W. Neurological symptoms as a feature of the antiphospholipid syndrome. Semin Thromb Hemost. 2008; 34 286-289
15 Tincani A, Bazzani C, Zingarelli S, Lojacono A. Lupus and the antiphospholipid syndrome in pregnancy and obstetrics: clinical characteristics, diagnosis, pathogenesis, and treatment. Semin Thromb Hemost. 2008; 34 267-273
16 Sourlier J P, Boffa M C. Avortements à répétition, thromboses, et anticoagulant circulant anti-thromoboplastine. Nouv Presse Med (Paris). 1980; 9 859-864
17 Nilsson I M, Asstedt B, Hedner D, Berezin B. Intrauterine death and circulating anticoagulant (“antithromboplastin”). Acta Med Scand. 1975; 197 153-159
18 Pierangeli S S, Chen P P, Elena R et al.. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost. 2008; 34 236-250
19 Galli M, Reber G, de Moerloose P, de Groot P G. Invitation to a debate on the serological criteria that define the antiphospholipid syndrome. J Thromb Haemost. 2008; 6 399-401
20 Pierangeli S S, Harris E N. A quarter of a century in anticardiolipin antibody testing and attempted standardization has led us to here, which is?. Semin Thromb Hemost. 2008; 34 , (in press)
21 Andreoli L, Rizzini S, Allegri S, Meroni P, Tincani A. Are the current attempts at standardization of antiphospholipid antibodies still useful? Emerging technologies signal a shift in direction. Semin Thromb Hemost. 2008; 34 , (in press)
22 Reber G, Boehlen F, de Moerloose P. Technical aspects in laboratory testing for antiphospholipid antibodies: Is standardization an impossible dream?. Semin Thromb Hemost. 2008; 34 , (in press)
23 Favaloro E J, Wong R C. Laboratory testing and identification of antiphospholipid antibodies and the antiphospholipid syndrome: limitations, standardization, and clinical utility. Semin Thromb Hemost. 2008; 34 , (in press)
24 Wong R C, Wilson R J, Pollock W, Steele R H, Gillis D. Anti-cardiolipin antibody testing and reporting practices among laboratories participating in a large external Quality Assurance Program. Pathology. 2004; 36 174-181
25 Wong R CW, Gillis D, Adelstein S et al.. Consensus guidelines on anti-cardiolipin antibody testing and reporting. Pathology. 2004; 36 63-68
26 Wong R C, Favaloro E J, Adelstein S et al.. Consensus guidelines on anti-beta 2 glycoprotein I testing and reporting. Pathology. 2008; 40 58-63
27 McCarthy G A et al.. Seronegative APS (SNAPS) in 53 patients: seroconversion rate at 3.5yrs [abstract]. J Autoimmun. 2000; 15 , OC35
28 Hunt B J. Paediatric antiphospholipid antibodies and antiphospholipid syndrome. Semin Thromb Hemost. 2008; 34 274-281
29 Miesbach W. Antiphospholipid antibodies and antiphospholipid syndrome in patients with malignancies: features, incidence, identification, and treatment. Semin Thromb Hemost. 2008; 34 282-285
30 Espinosa G, Bucciarelli S, Asherson R A, Cervera R. Morbidity and mortality in the catastrophic antiphospholipid syndrome: pathophysiology, causes of death, and prognostic factors. Semin Thromb Hemost. 2008; 34 290-294
31 Wilson W A, Gharavi A E, Koike T et al.. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999; 42 1309-1311
32 Lockshin M D, Sammaritano L R, Schwartzman S. Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum. 2000; 43 440-443
33 Galli M. Clinical utility of laboratory tests used to identify antiphospholipid antibodies and to diagnose the antiphospholipid syndrome. Semin Thromb Hemost. 2008; 34 , (in press)
34 de Groot P G, Derksen R H, de Laat B. Twenty-two years of failure to set-up undisputed assays to detect patients with the antiphospholipid antibodies. Semin Thromb Hemost. 2008; 34 , (in press)
35 Miret C, Cervera R, Reverter J C et al.. Antiphospholipid syndrome without antiphospholipid antibodies at the time of the thrombotic event: transient 'seronegative' antiphospholipid syndrome?. Clin Exp Rheumatol. 1997; 15 541-544
36 Helbert M, Bodger S, Cavenagh J et al.. Optimising testing for phospholipid antibodies. J Clin Pathol. 2001; 54 693-698
37 Khamashta M A, Cuadrado M J, Mujic F et al.. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 1995; 332 993-997
38 Crowther M A, Ginsberg J S, Julian J et al.. Comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003; 349 1133-1138
39 Finazzi G, Marchioli R, Brancaccio V et al.. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. 2005; 3 848-853
40 Erkan D, Harrison M J, Levy R et al.. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 2007; 56 2382-2391
41 Farquharson R G, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized controlled trial of treatment. Obstet Gynecol. 2002; 100 408-413
42 Silver R K, MacGregor S N, Sholl J S et al.. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. Am J Obstet Gynecol. 1993; 169 1411-1417
43 Cowchock F S, Reece E A, Balaban D, Branch D W, Plouffe L. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol. 1992; 166 1318-1327
44 Laskin C A, Bombardier C, Hannah M E et al.. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med. 1997; 337 148-153
45 Kutteh W H, Rote N S, Silver R K. Antiphospholipid antibodies and reproduction: the antiphospholipid antibody syndrome. Am J Reprod Immunol. 1999; 41 133-152
46 Asherson R A, Espinosa G, Menahem S et al.. Relapsing catastrophic antiphospholipid syndrome: report of three cases. Semin Arthritis Rheum. 2008; 37 366-372
47 Rubenstein E, Arkfeld D G, Metyas S et al.. Rituximab treatment for resistant antiphospholipid syndrome. J Rheumatol. 2006; 33 355-357
48 Erre G L, Pardini S, Faedda R, Passiu G. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus. 2008; 17 50-55
49 Adams M. Novel considerations in the pathogenesis of the antiphospholipid syndrome: involvement of the tissue factor pathway of blood coagulation. Semin Thromb Hemost. 2008; 34 251-255

Dr. Richard C.W Wong

Division of Immunology, Pathology Queensland (Central Laboratory), Level 4, Block 7

Royal Brisbane and Womens Hospital, Herston, Queensland 4029, Australia

Email: richard_wong@health.qld.gov.au